Posted On: 02/02/2015 8:52:28 AM
Post# of 579
Bio-AMD potential
Millions of dollars and years of research went into the COAG device, which Bio-AMD bought the rights to out of bankruptcy proceedings for about $5,000 USD. I'm sure many biotech investors recall how Questcor Pharmaceuticals (QCOR) bought the rights for Acthar gel out of bankruptcy for $100,000...a drug so successful that Questcor was bought out by Mallinckrodt PLC for $5.6 billion last year. While that is an extreme example, it vividly demonstrates the potential for technology that's obtained inexpensively to richly reward shareholders.
Millions of dollars and years of research went into the COAG device, which Bio-AMD bought the rights to out of bankruptcy proceedings for about $5,000 USD. I'm sure many biotech investors recall how Questcor Pharmaceuticals (QCOR) bought the rights for Acthar gel out of bankruptcy for $100,000...a drug so successful that Questcor was bought out by Mallinckrodt PLC for $5.6 billion last year. While that is an extreme example, it vividly demonstrates the potential for technology that's obtained inexpensively to richly reward shareholders.
(0)
(0)
